CompletedNCT00181779
Aripiprazole for mania in children and adolescents with bipolarity
About this title
Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar Disorder
Read the official source — NCT00181779Medication studyAges 6–17United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 6 years to 17 years. Other eligibility criteria applied.
- Listed locations
- CambridgeSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateFebruary 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 20
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT00181779
- Official title
Show the full official title
Open-Label Pilot Study of Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cambridge
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including aripiprazole (Abilify).
Who was this study for?
This study was for people with bipolarity. Listed age limits: 6 years to 17 years. Other eligibility criteria applied.
